What Is DHEA

DHEA (dehydroepiandrosterone) is a steroid hormone produced predominantly by the adrenal glands, with smaller contributions from the gonads and brain. It is the most abundant circulating steroid hormone in the human body and serves as the principal precursor from which the body manufactures testosterone, estrogen, and several other hormones. Because DHEA production declines substantially with age, it has become one of the most widely discussed hormones in longevity and anti-aging contexts.

The age-related decline in DHEA is among the most consistent endocrine changes observed in human aging. Between peak production in the mid-twenties and the seventh decade of life, circulating DHEA-S (the sulfated storage form) can fall by 80 percent or more. This decline parallels many hallmarks of aging, including loss of lean muscle mass, reduced bone mineral density, diminished immune competence, and changes in mood and cognitive function. Epidemiological studies have found associations between low DHEA-S levels and increased cardiovascular risk, frailty, and all-cause mortality, though such associations do not establish causation.

From a longevity perspective, DHEA occupies an unusual position. It sits upstream of multiple hormonal pathways, meaning its decline has cascading effects on the entire steroid hormone network. Unlike direct hormone replacement with testosterone or estrogen, DHEA supplementation provides a substrate that the body can theoretically allocate to whichever downstream hormone it needs most. Whether this theoretical advantage translates into meaningful clinical outcomes for healthy aging adults is an area where evidence remains mixed.

DHEA is synthesized from cholesterol through a series of enzymatic steps in the adrenal cortex, beginning with the conversion of cholesterol to pregnenolone by the enzyme CYP11A1, and then from pregnenolone to DHEA by CYP17A1. Once released into the bloodstream, most DHEA is quickly sulfated into DHEA-S by sulfotransferase enzymes. DHEA-S acts as a circulating reservoir; peripheral tissues can convert it back to DHEA as needed and then further metabolize it into androstenedione, testosterone, dihydrotestosterone (DHT), estrone, and estradiol through tissue-specific enzymes including 3β-hydroxysteroid dehydrogenase and aromatase.

This peripheral conversion is a defining feature of DHEA biology. Rather than acting like a single hormone with a single receptor, DHEA functions as a distributed precursor. The ultimate hormonal product depends on which enzymes are expressed in a given tissue. In bone, for instance, local conversion to estrogen may support osteoblast activity. In muscle, conversion to androgens may contribute to protein synthesis. The brain also expresses DHEA-metabolizing enzymes and may use locally produced neurosteroids to modulate GABA and NMDA receptor activity, which is relevant to mood, memory, and neuroprotection.

Beyond its role as a precursor, DHEA and DHEA-S appear to have some direct biological actions. Laboratory studies suggest DHEA can influence endothelial function, reduce inflammatory cytokine production, and modulate insulin sensitivity through mechanisms that may not require conversion to sex hormones. Some of these effects have been attributed to interaction with sigma-1 receptors and peroxisome proliferator-activated receptors (PPARα), though the clinical significance of these receptor interactions at physiological DHEA concentrations remains under investigation.

DHEA supplements are most commonly available as oral capsules or tablets containing micronized DHEA, which improves absorption compared to non-micronized forms. Sublingual tablets and troches are also available and may deliver DHEA more directly into the bloodstream while partially bypassing first-pass liver metabolism, though comparative bioavailability data are limited. Topical DHEA creams are used in some clinical settings, with the rationale that transdermal delivery may favor conversion to androgens in local tissue rather than systemic estrogen production, though this claim is not fully validated.

Intravaginal DHEA (marketed as prasterone) is a distinct pharmaceutical preparation approved in several countries specifically for the treatment of postmenopausal vulvovaginal atrophy. This localized delivery targets tissue that expresses the enzymes needed for local estrogen synthesis without producing meaningful systemic hormone elevation. For general supplementation purposes, oral micronized capsules remain the most widely studied and commonly used form.

Clinical trials have typically used doses between 25 and 100 mg per day, with 25 to 50 mg being the most common range in longevity-oriented protocols. Women generally require lower doses than men because they are more sensitive to the androgenic conversion products of DHEA. Starting at the lower end (10 to 25 mg for women, 25 mg for men) and titrating based on follow-up DHEA-S and sex hormone blood work is a common clinical approach.

Timing of dosing matters modestly. DHEA secretion follows a diurnal rhythm similar to cortisol, peaking in the morning hours. Taking supplemental DHEA in the morning aligns with this natural pattern and may reduce the likelihood of sleep disturbance, which some users report with evening dosing. The goal of supplementation is typically to restore DHEA-S levels to the mid-range for a younger adult (roughly corresponding to levels seen in the thirties), rather than to maximize levels. Exceeding the physiological range increases the risk of unwanted hormonal side effects without established additional benefit.

Because DHEA is sold as a dietary supplement in the United States (and some other jurisdictions) rather than a regulated pharmaceutical, product quality varies considerably. Third-party testing certifications from organizations such as NSF International, USP, or Informed Sport provide some assurance that the product contains the labeled dose without significant contaminants. Independent testing has occasionally found DHEA supplements with actual hormone content differing by 20 percent or more from the label claim, making third-party verification particularly relevant for a hormone precursor where dosing precision matters.

Micronized DHEA is preferred for oral supplementation because particle size reduction improves dissolution and bioavailability. Products should clearly state "micronized" on the label. Pharmaceutical-grade DHEA, when available, offers tighter manufacturing tolerances than supplement-grade material. Users should also verify that the product contains no undisclosed ingredients, as some DHEA supplements have been found to contain additional hormones or prohormones not listed on the label.

The clinical evidence on DHEA supplementation is substantial in volume but mixed in conclusions. Several randomized controlled trials in older adults have examined DHEA at doses of 25 to 100 mg daily for periods ranging from several months to two years. Some of these trials report modest improvements in bone mineral density, particularly at the hip and spine, and small gains in lean body mass. Effects on skin quality (thickness, hydration, sebum production) have been observed in multiple studies. However, large, well-designed trials have generally failed to show significant improvements in cognitive function, cardiovascular outcomes, or overall quality of life in healthy older adults taking DHEA.

The evidence is somewhat stronger in specific subpopulations. Women with adrenal insufficiency, who produce almost no endogenous DHEA, tend to show more consistent benefits in well-being, libido, and mood with DHEA replacement. Intravaginal DHEA (prasterone) has been studied in randomized trials for postmenopausal vulvovaginal atrophy and has received regulatory approval for that indication in several countries. In men, the effects of oral DHEA on testosterone levels and related outcomes have been less consistent, likely because men have alternative testosterone production pathways through the testes. Observational data linking higher DHEA-S levels to lower mortality risk are suggestive but cannot establish that supplementation would reproduce this association.

Because DHEA converts to sex hormones, it can produce androgenic side effects including acne, oily skin, facial hair growth in women, and scalp hair thinning. In theory, raising estrogen or testosterone levels could stimulate growth of hormone-sensitive tissues, which is why individuals with a personal or family history of breast, prostate, ovarian, or uterine cancer are generally advised to avoid DHEA or use it only under close clinical supervision. DHEA may also interact with insulin-sensitizing medications, anticoagulants, and other hormone therapies. Liver enzyme elevations have been reported rarely at higher doses. Over-the-counter availability in some countries can create a false sense that DHEA is as benign as a vitamin; it is a hormone precursor with real endocrine effects, and unsupervised use without baseline testing carries the risk of pushing hormone levels into undesirable ranges.